Newsfileยท2025-11-10 18:47Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by December 15, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against MoonLake - The complaint alleges that during the class period, the defendants made false or misleading statements and failed to disclose material facts regarding the differences between Nanobodies and monoclonal antibodies [5]. - Specific claims include that SLK and BIMZELX target the same inflammatory cytokines, and that SLK's Nanobody structure does not provide superior clinical benefits compared to BIMZELX [5]. - The lawsuit asserts that when the true information became public, investors suffered damages due to the misleading statements made by the defendants [5].